BioAtla is a global biotechnology company with operations in San Diego, California, and Beijing, China. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing. By utilizing its proprietary technologies of product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and for its internal programs. BioAtla has over 100 patents issued and pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/11/16 | $45,000,000 | |||
| 07/16/20 | $72,500,000 | Series D |
Boxer Capital Cormorant Asset Management Farallon Capital Management HBM Healthcare Investments  Janus Henderson Investors Pappas Capital Pfizer Venture Investments Soleus Capital | undisclosed |
